Literature DB >> 18695604

Emergence of the USA300 strain of methicillin-resistant Staphylococcus aureus in a burn-trauma unit.

Lucy A Wibbenmeyer1, Gerald P Kealey, Barbara A Latenser, Daniel J Diekema, Ingrid M Williams, Stacy L Coffman, Patricia L Winokur, Jennifer S Kroeger, Robert W Lewis, Loreen A Herwaldt.   

Abstract

Community-associated methicillin-resistant Staphylococcus aureus (MRSA), particularly USA300, is a major pathogen in the outpatient setting. We suspected that USA300 had been introduced into our burn-trauma unit (BTU) when three burn patients presented with numerous simultaneous abscesses. We did molecular typing on 206 MRSA isolates from all patients on the BTU who had MRSA isolated from either nares cultures or clinical specimens obtained between April 11, 2002 and October 24, 2006. We reviewed medical records for all patients who had USA300 and for 75 control patients. Twenty-five of 206 (12.1%) patients who were colonized (n = 3) or infected (n = 22) with MRSA had USA300. Thirteen patients had abscesses drained surgically and eight had necrotizing fasciitis excised. Seven patients had burns (mean burn size 11.8 +/- 3.4%), of who four (66.7%) acquired numerous simultaneous (3-33) abscesses. Fourteen patients acquired USA300 outside of the BTU, and three acquired this strain on the BTU. Cases were more likely to have been hospitalized or to have had an operation in the 6 months before they were hospitalized than were controls (P = .001 for both). To our knowledge, this is the first study to describe numerous simultaneous MRSA abscesses in burn patients. The MRSA strain USA300 may be introduced onto burn units from the community by patients admitted with skin and soft tissue infections, especially abscesses and necrotizing fasciitis. Burn patients may be at risk for numerous abscesses with USA300, because they have open wounds and their immune systems may be compromised.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695604     DOI: 10.1097/BCR.0b013e3181848b8f

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  6 in total

1.  Timeline of health care-associated infections and pathogens after burn injuries.

Authors:  David van Duin; Paula D Strassle; Lauren M DiBiase; Anne M Lachiewicz; William A Rutala; Timothy Eitas; Robert Maile; Hajime Kanamori; David J Weber; Bruce A Cairns; Sonia Napravnik; Samuel W Jones
Journal:  Am J Infect Control       Date:  2016-10-11       Impact factor: 2.918

Review 2.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  Increasing burden of methicillin-resistant Staphylococcus aureus hospitalizations at US academic medical centers, 2003-2008.

Authors:  Michael Z David; Sofia Medvedev; Samuel F Hohmann; Bernard Ewigman; Robert S Daum
Journal:  Infect Control Hosp Epidemiol       Date:  2012-06-11       Impact factor: 3.254

4.  The epidemiology of methicillin-resistant Staphylococcus aureus on a burn trauma unit.

Authors:  Marin Schweizer; Melissa Ward; Sandra Cobb; Jennifer McDanel; Laurie Leder; Lucy Wibbenmeyer; Barbara Latenser; Daniel Diekema; Loreen Herwaldt
Journal:  Infect Control Hosp Epidemiol       Date:  2012-09-21       Impact factor: 3.254

Review 5.  Emerging infections in burns.

Authors:  Ludwik K Branski; Ahmed Al-Mousawi; Haidy Rivero; Marc G Jeschke; Arthur P Sanford; David N Herndon
Journal:  Surg Infect (Larchmt)       Date:  2009-10       Impact factor: 2.150

6.  Preparation and evaluation of chitosan-polyvinyl alcohol/polyhexamethylene guanidine hydrochloride antibacterial dressing to accelerate wound healing for infectious skin repair.

Authors:  Xiaotong Yue; Lingying Liu; Yushou Wu; Xiangyu Liu; Shaozeng Li; Zihao Zhang; Shaofang Han; Xiaoteng Wang; Yang Chang; Hailiang Bai; Jiake Chai; Sen Hu; Hongyu Wang
Journal:  Ann Transl Med       Date:  2021-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.